Ap
Apeloa Pharmaceutical Co., Ltd.
Manufacturer
📅 Est. 1989
3
Products
0
Inquiries
54
Profile Views
Company Profile
Apeloa, founded in 1989, is a publicly traded company as part of the Hengdian Group. Headquartered in Hengdian, Zhejiang, Apeloa has over 7,000 employees worldwide. Apeloa is China's top 2 exporter of APIs and the top 5 CDMO companies. It also ranks 43rd among China's pharmaceutical companies.
Apeloa's core businesses include API, CDMO, FDF, and ACI, with seven API manufacturing sites (five chemical synthesis and two fermentation) and two drug product sites. Our products cover cardiovascular, anti-infection, psychotropic, and anti-cancer treatments, with production bases in Zhejiang, Shandong, and Anhui. Since 2007, our main API manufacturing sites have passed audits by NMPA, US FDA, EMEA, and PMDA, establishing us as a leading API enterprise. Our CDMO business maintains strategic partnerships with top pharmaceutical companies globally, offering comprehensive services and sustaining high growth. Apeloa's brands, "Baishixin" and "Tianliwei," have been widely recognized, and our first extended-release product has successfully entered the U.S. market.
Apeloa implements the development strategy of "Global API Leader, CDMO Excellence, High-quality & Affordable Medicine, Expanding Aesthetic & Care Ingredients", with annual R&D expenses exceeding 5% of revenue. We support leading technology platforms with over 1,300 scientists and collaborations with top universities. Our philosophy emphasizes technology driven, high-standard compliance, and cost efficiency, aiming to be a global leading technology-driven pharmaceutical manufacturer solutions provider.
Company Statistics:
- Top 43 Chinese pharmaceutical industry enterprises
- Ranked 2nd in the Country for the Export of Chemical API
- Top 5 Small Molecule CDMO Companies in China
- R&D Team of More Than 1,300 People
Mission: Technology for Health
Vision: To Be a Global Leading Technology-Driven Pharmaceutical Manufacturing Solutions Provider
Scientific Advisory Board:
Established in December 2022, the Apeloa Scientific Advisory Board (ASAB) is dedicated to providing strategic direction and planning advice for the company, participating in the initiation and evaluation of major projects, and the recruitment and development of key talents. The 2nd ASAB is composed of six renowned experts in the field of biomedicine, specializing in areas such as organic chemical synthesis, synthetic biology, biomanufacturing engineering technology, chemical engineering and microfluidic technology, pharmaceutical engineering and processes, and drug molecular design and process development.
Global Locations: China, USA, Germany, Japan
Apeloa's core businesses include API, CDMO, FDF, and ACI, with seven API manufacturing sites (five chemical synthesis and two fermentation) and two drug product sites. Our products cover cardiovascular, anti-infection, psychotropic, and anti-cancer treatments, with production bases in Zhejiang, Shandong, and Anhui. Since 2007, our main API manufacturing sites have passed audits by NMPA, US FDA, EMEA, and PMDA, establishing us as a leading API enterprise. Our CDMO business maintains strategic partnerships with top pharmaceutical companies globally, offering comprehensive services and sustaining high growth. Apeloa's brands, "Baishixin" and "Tianliwei," have been widely recognized, and our first extended-release product has successfully entered the U.S. market.
Apeloa implements the development strategy of "Global API Leader, CDMO Excellence, High-quality & Affordable Medicine, Expanding Aesthetic & Care Ingredients", with annual R&D expenses exceeding 5% of revenue. We support leading technology platforms with over 1,300 scientists and collaborations with top universities. Our philosophy emphasizes technology driven, high-standard compliance, and cost efficiency, aiming to be a global leading technology-driven pharmaceutical manufacturer solutions provider.
Company Statistics:
- Top 43 Chinese pharmaceutical industry enterprises
- Ranked 2nd in the Country for the Export of Chemical API
- Top 5 Small Molecule CDMO Companies in China
- R&D Team of More Than 1,300 People
Mission: Technology for Health
Vision: To Be a Global Leading Technology-Driven Pharmaceutical Manufacturing Solutions Provider
Scientific Advisory Board:
Established in December 2022, the Apeloa Scientific Advisory Board (ASAB) is dedicated to providing strategic direction and planning advice for the company, participating in the initiation and evaluation of major projects, and the recruitment and development of key talents. The 2nd ASAB is composed of six renowned experts in the field of biomedicine, specializing in areas such as organic chemical synthesis, synthetic biology, biomanufacturing engineering technology, chemical engineering and microfluidic technology, pharmaceutical engineering and processes, and drug molecular design and process development.
Global Locations: China, USA, Germany, Japan
